MTOR and neoplasm: In summary, our results, as shown in Figure 7, demonstrate that BTK-mTOR inhibition disrupts the population of GBM CSCs and contributes to normalizing GBM vascularization, which in turn facilitates the delivery of anticancer drugs and reduces the hypoxia of tumor cells.